You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
The purpose of this volume in the Progress in Inflammation Research series is to provide the biomedical and clinical researcher with a state-of-the-art insight in the role of cytokines in joint inflammation and joint destruction. This is of relevance for better understanding of key processes in diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA). Apart from the impact of old and novel cytokines on joint tissues, the various chapters address the issue of targeted therapy with biological response modifiers and future interventions with carefully designed inhibitors. Spe cial attention is given to elements of synovial cell activation, cell-cell interaction, cytokine interplay as ...
Rheumatoid arthritis (RA) is the most common and most severe form of inflammatory arthritis. The pathogenesis of RA has been the subject of intense research for several decades. The prevailing hypotheses have changed over the years, and have attempted to incorporate the most recent data. Although T cells represent an important component of the cells which infiltrate the joint synovium, their contribution at a late stage of the disease remains a matter of debate. The goal of this book is to outline the major arguments and data suggesting that T cells may, or may not, be central players in the pathogenesis of chronic RA. While each of the editors and authors has his/her own bias (as will be clear by reading the respective chapters), our hope is that the readers will enjoy a complete and balanced view of the critical questions and experiments. This is not just an intellectual exercise since the direction of future therapeutic interventions depends heavily on how one interprets the pathogenesis of RA and the contribution of T cells.
First multi-year cumulation covers six years: 1965-70.
On May 24-27,1992 the European Society ofOsteoarthrology (ESOA) held its 19th sympo sium in Noordwijkerhout, The Netherlands. The symposium was entitled "Joint destruction in arthritis and osteoarthritis" and sought to combine both clinical and experimental studies in this field. The present volume contains the proceedings of this meeting. The ESOA has organized most of its symposia in the eastern part of Europe, thanks to major input from Stanislav Havelka, who in recent years has been supported by Heikki Helminen. In appreciation of his efforts Stan Havelka was granted Honorary Presidentship of the ESOA at the meeting. In the era of European unification it seemed desirable to create a strong Uni fied European Society, which would organize major meetings in both parts of Europe. Cartilage and bone research is expanding rapidly and the number of meetings in this field is continually growing. In line with these developments discussions took place with the recent Iy founded "Eular Workshop on Bone and Cartilage Research" and the "Osteoarthritis Re search Society (OARS)".
The IL-17 cytokines represent a novel family of cytokines, which defines a new effector T cell, the Th17 cell, and extend the Th1-Th2 paradigm. Th17 cells in part co-express at least IL-17A and IL-17F, IL-21 and IL-22. IL-17 A/F are produced by T cells ( and ), iNKT cells, and possibly neutrophils, dendritic cells and Paneth cells. The regulation of IL-17 family member’s expression, and the identification of effector mechanisms are an area of intense current research. Recognized regulators of IL-17A expression include the nuclear receptor ROR t, proinflammatory cyt- ines such as IL-1, IL-6 with TGF- , IL-21, IL-23 IL-25 in the absence of IFN- and IL-4, which are discussed. Recent data sugg...
This volume focuses on therapeutic targets that were identified after TNF blockade. All these targets have recently been registered or are currently under development for the treatment of rheumatoid arthritis. Each chapter explores the biological rationale of a distinct therapeutic target in great detail. Readers will discover the latest in vitro work, animal models, and results from clinical trials.
The purpose of this volume in the series Progress in Inflammation Research is to pro vide the biomedical researcher with a description of the state of the art of the devel opment and use of animal models of diseases with components of inflammation. Par ticularly highlighted are those models which can serve as in vivo correlates of diseases most commonly targeted for therapeutic intervention. The format is designed with the laboratory in mind; thus it provides detailed descriptions of the methodologies and uses of the most significant models. Also, new approaches to the development of future models in selected therapeutic areas have been highlighted. While emphasis is on the newest models, ne...